Dear Lyfebulb Community:
These are exciting times at Lyfebulb; with new opportunities and challenges we are growing our team and adding capabilities!
First, we are excited to announce Lisa Ricciardi as our newest board member. Ricciardi is a Life Sciences executive with deep business development and operational experience. She has worked for top pharmaceutical, payer, and molecular diagnostics firms, including Pfizer, Medco, and Foundation Medicine, as well as for Essex Woodlands Health Ventures, a global venture capital partnership. We are happy to welcome her into the Lyfebulb family.
Secondly, we would like to announce that Stephen Squinto, Lyfebulb co-founder, and venture partner at Orbimed, has assumed the position as chairman of Lyfebulb. Dr. Squinto has over 25 years of biotechnology industry experience and has received numerous honors and awards from academic and professional organizations for his scientific work. We are looking forward to working with Dr. Squinto to grow Lyfebulb this year.
Last, but not least, we have added Bruna Petrillo to our operational team as our Creative Director. Petrillo is a creative and passionate marketing strategist. She has worked in fashion marketing and fashion PR at start-up companies for the past three years. Prior to joining Lyfebulb, she was the marketing director for CARRIE HAMMER, where she assisted in revolutionizing the term ‘Role Models Not Runway Models.’
And, in case you missed it: Karin Hehenberger shared an important piece onHuffington Post asking: Why are venture capital firms less likely to invest in diabetes? Why is the average age of endocrinologists increasing, and why aren’t there more smaller public companies in the diabetes space? She argues that without the influx of talent, capital, and the right kind of media attention, we will never beat diabetes. Read more here.
The Lyfebulb Team